A Randomized controlled trial of clarithromycin 800 mg versus 400 mg as part of first-line triple therapy with vonoprazan for Helicobacter pylori gastritis

Phase 4

Recruiting

• Conditions: Helicobacter pylori gastritis

• Registration Number: JPRN-UMIN000045798
• Lead Sponsor: Takamatsu Red Cross Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-10-21
• Study Completion: 2022-05-13
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 516

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients who have histories of eradication therapy for Helicobacter pylori. 2. Patients who received any one of lansoprazole, esomeprazole, omeprazole, and vonoprazan within 2 weeks. 3. Patients who suggested or received a diagnosis of other infectious diseases. 4. Patients being treated for acute gastritis, advanced gastric cancer, and gastric MALT lymphoma. 5. Patients after gastrectomy. 6. Patients who have coexisting severe heart disease, liver disease, respiratory disease, metabolic disease, neuromuscular disease, and severe chronic renal failure (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2). 7. Patients who have a past history of allergy for vonoprazan, esomeprazole, amoxicillin, and clarithromycin. 8. Pregnancy or lactating women. 9. Patients requiring hospitalization..

Study & Design

• Study Type: Interventional
• Study Design: Not specified